David R. O'Reilly1, Victor Mascarenhas2, Mike Green3, Avian Townley3, Alan Potts3, and Alan McCaffery3. (1) Syngenta Biotechnology Inc, 3054 Cornwallis Road, RTP, Durham, NC 27709, (2) Syngenta Crop Protection, 410 Swing Road, Greensboro, NC 27419-8300, (3) Syngenta, 7145 58th Avenue, Vero Beach, FL 32967
Syngenta is currently developing cotton varieties that express both Vip3A and Cry1Ab toxins. The mode-of-action of Vip3A is different to that of Cry1Ab, and there is no cross-resistance between Vip3A and Cry toxins, so that a stack of Vip3A and Cry1Ab will represent an excellent product from the Insect Resistance Management (IRM) perspective. We are currently evaluating the high dose status of the components of this stack to help formulate the IRM strategy that we will propose for the product. In this paper, laboratory and field data assessing the high dose status of the Cry1Ab component of the stack are presented.
See more of Cotton Insect Research and Control Conference - Session B
See more of Cotton Insect Research and Control Conference
See more of The Beltwide Cotton Conferences, January 3-6 2006
